Share Price and Basic Stock Data
Last Updated: November 5, 2025, 4:28 pm
| PEG Ratio | -17.48 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
MK Proteins Ltd operates in the Edible Oils and Solvent Extraction industry, with a current market capitalization of ₹253 Cr and a share price of ₹6.75. The company reported sales of ₹315 Cr for the financial year ending March 2023, which represents an increase from ₹256 Cr in the previous year. However, sales are projected to decline to ₹245 Cr for FY 2024 before recovering to ₹268 Cr in FY 2025. The trailing twelve months (TTM) sales stood at ₹325 Cr, indicating a modest improvement in recent performance. The quarterly sales data shows fluctuations, with the latest figures for September 2023 at ₹13.64 Cr and December 2023 at ₹68.86 Cr, suggesting variability in demand or operational challenges. The highest sales recorded in the upcoming quarters are ₹137.20 Cr for March 2025 and ₹114.95 Cr for June 2025, signaling potential growth recovery after the dip in FY 2024. The company’s sales growth trajectory remains a focal point for stakeholders, particularly in the context of rising competition in the edible oils sector.
Profitability and Efficiency Metrics
MK Proteins Ltd’s profitability metrics reflect a mixed performance. The company’s operating profit margin (OPM) stood at 4.79%, which is relatively low compared to industry averages, indicating potential challenges in cost management or pricing strategies. The net profit for FY 2023 was ₹11 Cr, which is a slight increase from ₹10 Cr in FY 2022, but projected to decline to ₹8 Cr for FY 2025. The interest coverage ratio (ICR) is notably strong at 11.68x, suggesting that the company comfortably covers its interest obligations, which is a positive sign for creditors. However, the return on equity (ROE) at 12.08% and return on capital employed (ROCE) at 17.54% suggest that the company may not be utilizing its equity and capital as effectively as peers, which typically achieve higher returns. The cash conversion cycle (CCC) has lengthened to 142 days, indicating inefficiencies in working capital management that could potentially strain liquidity and operational agility.
Balance Sheet Strength and Financial Ratios
The balance sheet of MK Proteins Ltd reveals a mixed financial health profile. As of March 2025, total borrowings stood at ₹39 Cr, against reserves of ₹32 Cr, indicating a reliance on debt financing. The total liabilities have increased to ₹131 Cr, reflecting a rising financial obligation. The current ratio at 2.01x signifies a strong liquidity position, allowing the company to cover its short-term liabilities comfortably. However, the quick ratio at 0.12x indicates potential challenges in meeting immediate obligations without liquidating inventory. The price-to-book value (P/BV) ratio is reported at 3.26x, suggesting that the stock is trading at a premium relative to its book value, which may raise concerns among value investors. Overall, while the company maintains adequate liquidity, its increasing debt levels and high P/BV could deter risk-averse investors.
Shareholding Pattern and Investor Confidence
The shareholding structure of MK Proteins Ltd indicates a strong promoter presence, with promoters holding 74.82% of the total shares, which reflects confidence in the company’s long-term prospects. The public shareholding stands at 25.18%, with no foreign institutional investors (FIIs) reported, which may limit broader market participation and liquidity. The number of shareholders has significantly increased from 57 in March 2022 to 71,656 by June 2025, indicating growing retail interest in the stock. However, the absence of FIIs could signal caution among institutional investors regarding the company’s growth potential or operational challenges. This concentrated ownership might also raise governance concerns if the interests of minority shareholders are not adequately addressed. Overall, while the strong promoter holding can be seen as a strength, the lack of institutional backing may pose risks to share price stability and market perception.
Outlook, Risks, and Final Insight
The outlook for MK Proteins Ltd appears cautiously optimistic with several strengths and risks to consider. Positive indicators include a strong interest coverage ratio and a solid liquidity position, which provide a buffer against operational challenges. However, the company’s declining profitability margins and increasing cash conversion cycle raise concerns about operational efficiency. Key risks include dependence on debt financing and the absence of institutional investors, which could impact market stability and investor confidence. If the company can effectively address its working capital inefficiencies and enhance profitability through better cost management, it may reverse the current downward trend. Conversely, failure to improve operational metrics may lead to further declines in profitability and shareholder confidence. The company must navigate these challenges to unlock its potential in a competitive market landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of MK Proteins Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Modi Naturals Ltd | 582 Cr. | 444 | 667/320 | 17.1 | 92.8 | 0.00 % | 18.7 % | 29.2 % | 10.0 |
| IEL Ltd | 106 Cr. | 8.12 | 10.3/3.87 | 3.44 | 0.00 % | 2.51 % | 1.91 % | 1.00 | |
| Evexia Lifecare Ltd | 334 Cr. | 1.78 | 4.40/1.65 | 191 | 2.45 | 0.00 % | 0.30 % | 0.32 % | 1.00 |
| Diligent Industries Ltd | 64.4 Cr. | 2.70 | 5.12/1.45 | 23.9 | 2.71 | 0.00 % | 7.06 % | 6.09 % | 1.00 |
| CIAN Agro Industries & Infrastructure Ltd | 4,972 Cr. | 1,776 | 3,633/271 | 5,715 | 32.8 | 0.00 % | 8.54 % | 1.06 % | 10.0 |
| Industry Average | 9,889.13 Cr | 203.66 | 374.18 | 35.62 | 0.16% | 14.31% | 12.90% | 4.29 |
Quarterly Result
| Metric | Mar 2017 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 53.59 | 76.20 | 13.64 | 68.86 | 86.87 | 57.33 | 33.69 | 39.48 | 137.20 | 114.95 |
| Expenses | 51.69 | 72.21 | 13.00 | 65.30 | 78.44 | 53.59 | 31.46 | 37.69 | 132.55 | 109.44 |
| Operating Profit | 1.90 | 3.99 | 0.64 | 3.56 | 8.43 | 3.74 | 2.23 | 1.79 | 4.65 | 5.51 |
| OPM % | 3.55% | 5.24% | 4.69% | 5.17% | 9.70% | 6.52% | 6.62% | 4.53% | 3.39% | 4.79% |
| Other Income | 0.01 | 0.00 | 0.03 | 0.01 | 0.41 | 0.00 | 0.21 | 0.25 | 0.02 | 0.00 |
| Interest | 0.69 | 0.52 | 0.04 | 0.11 | 0.40 | 0.33 | 0.03 | 0.07 | 0.67 | 0.70 |
| Depreciation | 0.30 | 0.12 | 0.12 | 0.12 | 0.18 | 0.07 | 0.07 | 0.11 | 0.09 | 0.10 |
| Profit before tax | 0.92 | 3.35 | 0.51 | 3.34 | 8.26 | 3.34 | 2.34 | 1.86 | 3.91 | 4.71 |
| Tax % | 36.96% | 25.67% | 21.57% | 25.75% | 29.42% | 25.45% | 25.21% | 25.81% | 28.64% | 25.27% |
| Net Profit | 0.57 | 2.49 | 0.41 | 2.48 | 5.83 | 2.48 | 1.74 | 1.38 | 2.80 | 3.51 |
| EPS in Rs | 0.02 | 0.07 | 0.01 | 0.07 | 0.16 | 0.07 | 0.05 | 0.04 | 0.07 | 0.09 |
Last Updated: August 20, 2025, 7:35 am
Below is a detailed analysis of the quarterly data for MK Proteins Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 114.95 Cr.. The value appears to be declining and may need further review. It has decreased from 137.20 Cr. (Mar 2025) to 114.95 Cr., marking a decrease of 22.25 Cr..
- For Expenses, as of Jun 2025, the value is 109.44 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 132.55 Cr. (Mar 2025) to 109.44 Cr., marking a decrease of 23.11 Cr..
- For Operating Profit, as of Jun 2025, the value is 5.51 Cr.. The value appears strong and on an upward trend. It has increased from 4.65 Cr. (Mar 2025) to 5.51 Cr., marking an increase of 0.86 Cr..
- For OPM %, as of Jun 2025, the value is 4.79%. The value appears strong and on an upward trend. It has increased from 3.39% (Mar 2025) to 4.79%, marking an increase of 1.40%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.02 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.02 Cr..
- For Interest, as of Jun 2025, the value is 0.70 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.67 Cr. (Mar 2025) to 0.70 Cr., marking an increase of 0.03 Cr..
- For Depreciation, as of Jun 2025, the value is 0.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.09 Cr. (Mar 2025) to 0.10 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 4.71 Cr.. The value appears strong and on an upward trend. It has increased from 3.91 Cr. (Mar 2025) to 4.71 Cr., marking an increase of 0.80 Cr..
- For Tax %, as of Jun 2025, the value is 25.27%. The value appears to be improving (decreasing) as expected. It has decreased from 28.64% (Mar 2025) to 25.27%, marking a decrease of 3.37%.
- For Net Profit, as of Jun 2025, the value is 3.51 Cr.. The value appears strong and on an upward trend. It has increased from 2.80 Cr. (Mar 2025) to 3.51 Cr., marking an increase of 0.71 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.09. The value appears strong and on an upward trend. It has increased from 0.07 (Mar 2025) to 0.09, marking an increase of 0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:56 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 122 | 123 | 145 | 165 | 172 | 157 | 194 | 311 | 256 | 315 | 245 | 268 | 325 |
| Expenses | 119 | 119 | 141 | 160 | 166 | 152 | 189 | 295 | 240 | 298 | 229 | 255 | 311 |
| Operating Profit | 3 | 4 | 4 | 5 | 6 | 5 | 5 | 16 | 16 | 17 | 17 | 13 | 14 |
| OPM % | 2% | 3% | 3% | 3% | 3% | 3% | 2% | 5% | 6% | 5% | 7% | 5% | 4% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| Profit before tax | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 14 | 14 | 15 | 15 | 11 | 13 |
| Tax % | 33% | 32% | 31% | 35% | 35% | 28% | 26% | 27% | 27% | 27% | 28% | 27% | |
| Net Profit | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 10 | 10 | 11 | 11 | 8 | 9 |
| EPS in Rs | 0.82 | 1.40 | 1.20 | 0.04 | 0.04 | 0.04 | 0.05 | 0.28 | 0.27 | 0.29 | 0.30 | 0.22 | 0.25 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 400.00% | 0.00% | 10.00% | 0.00% | -27.27% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% | 100.00% | -100.00% | 400.00% | -400.00% | 10.00% | -10.00% | -27.27% |
MK Proteins Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 7% |
| 3 Years: | 2% |
| TTM: | 44% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 35% |
| 3 Years: | -7% |
| TTM: | -16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 49% |
| 3 Years: | 39% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 23% |
| 3 Years: | 18% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 10:00 am
Balance Sheet
Last Updated: June 16, 2025, 11:46 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.68 | 0.68 | 0.68 | 3 | 4 | 4 | 4 | 4 | 4 | 13 | 38 | 38 |
| Reserves | 1 | 2 | 3 | 2 | 11 | 13 | 15 | 25 | 35 | 37 | 24 | 32 |
| Borrowings | 28 | 20 | 26 | 31 | 33 | 26 | 31 | 25 | 37 | 46 | 20 | 39 |
| Other Liabilities | 2 | 13 | 10 | 12 | 8 | 4 | 7 | 13 | 10 | 8 | 15 | 22 |
| Total Liabilities | 32 | 35 | 39 | 47 | 56 | 47 | 57 | 67 | 86 | 103 | 96 | 131 |
| Fixed Assets | 3 | 6 | 7 | 7 | 6 | 4 | 3 | 2 | 3 | 3 | 3 | 4 |
| CWIP | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 7 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 26 | 29 | 32 | 40 | 50 | 43 | 53 | 65 | 83 | 100 | 88 | 120 |
| Total Assets | 32 | 35 | 39 | 47 | 56 | 47 | 57 | 67 | 86 | 103 | 96 | 131 |
Below is a detailed analysis of the balance sheet data for MK Proteins Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 38.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 38.00 Cr..
- For Reserves, as of Mar 2025, the value is 32.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Mar 2024) to 32.00 Cr., marking an increase of 8.00 Cr..
- For Borrowings, as of Mar 2025, the value is 39.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 20.00 Cr. (Mar 2024) to 39.00 Cr., marking an increase of 19.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 22.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.00 Cr. (Mar 2024) to 22.00 Cr., marking an increase of 7.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 131.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 96.00 Cr. (Mar 2024) to 131.00 Cr., marking an increase of 35.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2024) to 4.00 Cr., marking an increase of 1.00 Cr..
- For CWIP, as of Mar 2025, the value is 7.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2024) to 7.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 120.00 Cr.. The value appears strong and on an upward trend. It has increased from 88.00 Cr. (Mar 2024) to 120.00 Cr., marking an increase of 32.00 Cr..
- For Total Assets, as of Mar 2025, the value is 131.00 Cr.. The value appears strong and on an upward trend. It has increased from 96.00 Cr. (Mar 2024) to 131.00 Cr., marking an increase of 35.00 Cr..
However, the Borrowings (39.00 Cr.) are higher than the Reserves (32.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -25.00 | -16.00 | -22.00 | -26.00 | -27.00 | -21.00 | -26.00 | -9.00 | -21.00 | -29.00 | -3.00 | -26.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 19 | 16 | 27 | 10 | 39 | 25 | 18 | 24 | 42 | 19 | 5 | 2 |
| Inventory Days | 62 | 70 | 57 | 83 | 69 | 75 | 79 | 48 | 80 | 91 | 134 | 170 |
| Days Payable | 6 | 39 | 22 | 23 | 12 | 6 | 8 | 10 | 8 | 6 | 19 | 29 |
| Cash Conversion Cycle | 75 | 47 | 62 | 70 | 97 | 94 | 89 | 62 | 114 | 104 | 120 | 142 |
| Working Capital Days | 69 | 11 | 9 | 20 | 44 | 32 | 36 | 36 | 55 | 57 | 77 | 81 |
| ROCE % | 10% | 14% | 13% | 12% | 11% | 8% | 8% | 29% | 23% | 20% | 19% | 13% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.22 | 0.30 | 8.51 | 24.42 | 24.91 |
| Diluted EPS (Rs.) | 0.22 | 0.30 | 8.51 | 24.42 | 24.91 |
| Cash EPS (Rs.) | 0.23 | 0.31 | 9.11 | 26.61 | 27.09 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.85 | 1.63 | 40.18 | 94.95 | 70.34 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.85 | 1.63 | 40.18 | 94.95 | 70.34 |
| Revenue From Operations / Share (Rs.) | 7.13 | 6.54 | 251.64 | 613.52 | 745.89 |
| PBDIT / Share (Rs.) | 0.34 | 0.45 | 13.66 | 37.85 | 38.31 |
| PBIT / Share (Rs.) | 0.33 | 0.44 | 13.06 | 35.66 | 36.13 |
| PBT / Share (Rs.) | 0.30 | 0.41 | 11.67 | 33.67 | 34.34 |
| Net Profit / Share (Rs.) | 0.22 | 0.29 | 8.51 | 24.42 | 24.91 |
| PBDIT Margin (%) | 4.82 | 6.94 | 5.42 | 6.16 | 5.13 |
| PBIT Margin (%) | 4.69 | 6.73 | 5.18 | 5.81 | 4.84 |
| PBT Margin (%) | 4.27 | 6.29 | 4.63 | 5.48 | 4.60 |
| Net Profit Margin (%) | 3.13 | 4.56 | 3.38 | 3.98 | 3.33 |
| Return on Networth / Equity (%) | 12.08 | 18.35 | 21.17 | 25.71 | 35.41 |
| Return on Capital Employeed (%) | 17.54 | 26.54 | 30.87 | 35.13 | 44.53 |
| Return On Assets (%) | 6.43 | 11.64 | 10.14 | 11.82 | 15.42 |
| Long Term Debt / Equity (X) | 0.01 | 0.00 | 0.05 | 0.06 | 0.15 |
| Total Debt / Equity (X) | 0.54 | 0.31 | 0.88 | 0.92 | 0.83 |
| Asset Turnover Ratio (%) | 2.36 | 2.44 | 3.30 | 3.33 | 5.02 |
| Current Ratio (X) | 2.01 | 2.53 | 1.96 | 1.88 | 1.92 |
| Quick Ratio (X) | 0.12 | 0.19 | 0.58 | 0.74 | 0.79 |
| Inventory Turnover Ratio (X) | 2.81 | 2.73 | 4.23 | 4.49 | 5.77 |
| Interest Coverage Ratio (X) | 11.68 | 16.02 | 9.86 | 18.96 | 21.31 |
| Interest Coverage Ratio (Post Tax) (X) | 8.60 | 11.53 | 7.14 | 13.23 | 14.86 |
| Enterprise Value (Cr.) | 264.44 | 389.87 | 957.87 | 116.65 | 57.72 |
| EV / Net Operating Revenue (X) | 0.98 | 1.59 | 3.04 | 0.45 | 0.18 |
| EV / EBITDA (X) | 20.49 | 22.85 | 56.03 | 7.39 | 3.61 |
| MarketCap / Net Operating Revenue (X) | 0.84 | 1.51 | 2.90 | 0.31 | 0.10 |
| Price / BV (X) | 3.26 | 6.07 | 18.17 | 2.02 | 1.13 |
| Price / Net Operating Revenue (X) | 0.84 | 1.51 | 2.90 | 0.31 | 0.10 |
| EarningsYield | 0.03 | 0.03 | 0.01 | 0.12 | 0.31 |
After reviewing the key financial ratios for MK Proteins Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.22. This value is below the healthy minimum of 5. It has decreased from 0.30 (Mar 24) to 0.22, marking a decrease of 0.08.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.22. This value is below the healthy minimum of 5. It has decreased from 0.30 (Mar 24) to 0.22, marking a decrease of 0.08.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 3. It has decreased from 0.31 (Mar 24) to 0.23, marking a decrease of 0.08.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.85. It has increased from 1.63 (Mar 24) to 1.85, marking an increase of 0.22.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.85. It has increased from 1.63 (Mar 24) to 1.85, marking an increase of 0.22.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 7.13. It has increased from 6.54 (Mar 24) to 7.13, marking an increase of 0.59.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 2. It has decreased from 0.45 (Mar 24) to 0.34, marking a decrease of 0.11.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.33. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.33, marking a decrease of 0.11.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.41 (Mar 24) to 0.30, marking a decrease of 0.11.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.22. This value is below the healthy minimum of 2. It has decreased from 0.29 (Mar 24) to 0.22, marking a decrease of 0.07.
- For PBDIT Margin (%), as of Mar 25, the value is 4.82. This value is below the healthy minimum of 10. It has decreased from 6.94 (Mar 24) to 4.82, marking a decrease of 2.12.
- For PBIT Margin (%), as of Mar 25, the value is 4.69. This value is below the healthy minimum of 10. It has decreased from 6.73 (Mar 24) to 4.69, marking a decrease of 2.04.
- For PBT Margin (%), as of Mar 25, the value is 4.27. This value is below the healthy minimum of 10. It has decreased from 6.29 (Mar 24) to 4.27, marking a decrease of 2.02.
- For Net Profit Margin (%), as of Mar 25, the value is 3.13. This value is below the healthy minimum of 5. It has decreased from 4.56 (Mar 24) to 3.13, marking a decrease of 1.43.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.08. This value is below the healthy minimum of 15. It has decreased from 18.35 (Mar 24) to 12.08, marking a decrease of 6.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.54. This value is within the healthy range. It has decreased from 26.54 (Mar 24) to 17.54, marking a decrease of 9.00.
- For Return On Assets (%), as of Mar 25, the value is 6.43. This value is within the healthy range. It has decreased from 11.64 (Mar 24) to 6.43, marking a decrease of 5.21.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.54. This value is within the healthy range. It has increased from 0.31 (Mar 24) to 0.54, marking an increase of 0.23.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 2.36. It has decreased from 2.44 (Mar 24) to 2.36, marking a decrease of 0.08.
- For Current Ratio (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has decreased from 2.53 (Mar 24) to 2.01, marking a decrease of 0.52.
- For Quick Ratio (X), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 1. It has decreased from 0.19 (Mar 24) to 0.12, marking a decrease of 0.07.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.81. This value is below the healthy minimum of 4. It has increased from 2.73 (Mar 24) to 2.81, marking an increase of 0.08.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.68. This value is within the healthy range. It has decreased from 16.02 (Mar 24) to 11.68, marking a decrease of 4.34.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.60. This value is within the healthy range. It has decreased from 11.53 (Mar 24) to 8.60, marking a decrease of 2.93.
- For Enterprise Value (Cr.), as of Mar 25, the value is 264.44. It has decreased from 389.87 (Mar 24) to 264.44, marking a decrease of 125.43.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1. It has decreased from 1.59 (Mar 24) to 0.98, marking a decrease of 0.61.
- For EV / EBITDA (X), as of Mar 25, the value is 20.49. This value exceeds the healthy maximum of 15. It has decreased from 22.85 (Mar 24) to 20.49, marking a decrease of 2.36.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has decreased from 1.51 (Mar 24) to 0.84, marking a decrease of 0.67.
- For Price / BV (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has decreased from 6.07 (Mar 24) to 3.26, marking a decrease of 2.81.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has decreased from 1.51 (Mar 24) to 0.84, marking a decrease of 0.67.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in MK Proteins Ltd:
- Net Profit Margin: 3.13%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.54% (Industry Average ROCE: 14.31%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.08% (Industry Average ROE: 12.29%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.6
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.12
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 26.7 (Industry average Stock P/E: 302.91)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.54
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 3.13%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Edible Oils & Solvent Extraction | Naraingarh Road, Village Garnala, Ambala District Haryana 134003 | compliancemkproteins@gmail.com http://www.mkproteins.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Parvind Kumar | Chairman |
| Mr. Parmod Kumar | Managing Director |
| Mr. Vinod Kumar | Whole Time Director |
| Ms. Laxmi Mandal | Independent Director |
| Mr. Tej Mohan Singh | Independent Director |
| Mrs. Shipra Jain | Independent Director |
| Mr. Raj Kumar | Non Executive Director |
FAQ
What is the intrinsic value of MK Proteins Ltd?
MK Proteins Ltd's intrinsic value (as of 05 November 2025) is 5.00 which is 25.48% lower the current market price of 6.71, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 252 Cr. market cap, FY2025-2026 high/low of 9.78/5.37, reserves of ₹32 Cr, and liabilities of 131 Cr.
What is the Market Cap of MK Proteins Ltd?
The Market Cap of MK Proteins Ltd is 252 Cr..
What is the current Stock Price of MK Proteins Ltd as on 05 November 2025?
The current stock price of MK Proteins Ltd as on 05 November 2025 is 6.71.
What is the High / Low of MK Proteins Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of MK Proteins Ltd stocks is 9.78/5.37.
What is the Stock P/E of MK Proteins Ltd?
The Stock P/E of MK Proteins Ltd is 26.7.
What is the Book Value of MK Proteins Ltd?
The Book Value of MK Proteins Ltd is 1.85.
What is the Dividend Yield of MK Proteins Ltd?
The Dividend Yield of MK Proteins Ltd is 0.00 %.
What is the ROCE of MK Proteins Ltd?
The ROCE of MK Proteins Ltd is 12.9 %.
What is the ROE of MK Proteins Ltd?
The ROE of MK Proteins Ltd is 12.4 %.
What is the Face Value of MK Proteins Ltd?
The Face Value of MK Proteins Ltd is 1.00.